OR WAIT null SECS
August 13, 2025
Article
Parent company Response Pharmaceuticals has announced RDX-002’s achievement of its primary endpoint, with more data to come from an ongoing extension.
August 06, 2025
July delivered 9 impactful advancements across the gamut of disciplines in cardiology.
August 04, 2025
Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.
July 31, 2025
Inclisiran can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in hypercholesterolemia.
July 10, 2025
Actual LLT use was significantly lower than the proportion of guideline-eligible patients for statins, ezetimibe, and PCSK9i.
July 04, 2025
Our recap of Q2 2025 in cardiology spotlights 3 FDA headlines, trial news, and new episodes of Don't Miss a Beat.
June 09, 2025
Phase 3 trials show enlicitide decanoate significantly lowers LDL cholesterol, offering a promising oral treatment for hyperlipidemia and cardiovascular risk.
June 03, 2025
Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.
May 29, 2025
The FDA approves hydrocortisone oral solution for pediatric adrenal insufficiency, enhancing dosing accuracy and ease for young patients and caregivers.
May 27, 2025
Prothena halts birtamimab development after missing key Phase 3 trial endpoints for AL amyloidosis, prompting workforce reductions and cost-cutting measures.
